{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:32:39Z","timestamp":1793568759911,"version":"4.5.0"},"reference-count":38,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>For children with growth hormone deficiency (GHD), treatment burden with daily somatropin injections [human growth hormone (hGH)] is high, which may lead to poor adherence and suboptimal overall treatment outcomes. Lonapegsomatropin (TransCon hGH) is an investigational long-acting, once-weekly prodrug for the treatment of GHD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study was to evaluate the efficacy and safety of once-weekly lonapegsomatropin vs daily somatropin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The heiGHt trial was a randomized, open-label, active-controlled, 52-week Phase 3 trial (NCT02781727).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>This trial took place at 73 sites across 15 countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>This trial enrolled and dosed 161 treatment-na\u00efve, prepubertal patients with GHD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Patients were randomized 2:1 to receive lonapegsomatropin 0.24 mg hGH\/kg\/week or an equivalent weekly dose of somatropin delivered daily.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>The primary end point was annualized height velocity (AHV) at week 52. Secondary efficacy end points included change from baseline in height SD scores (SDS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Least squares (LS) mean (SE) AHV at 52 weeks was 11.2 (0.2) cm\/year for lonapegsomatropin vs 10.3 (0.3) cm\/year for daily somatropin (P = 0.009), with lonapegsomatropin demonstrating both noninferiority and superiority over daily somatropin. LS mean (SE) height SDS increased from baseline to week 52 by 1.10 (0.04) vs 0.96 (0.05) in the weekly lonapegsomatropin vs daily somatropin groups (P = 0.01). Bone age\/chronological age ratio, adverse events, tolerability, and immunogenicity were similar between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The trial met its primary objective of noninferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-na\u00efve children with GHD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab529","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T11:49:31Z","timestamp":1626522571000},"page":"3184-3195","source":"Crossref","is-referenced-by-count":92,"title":["Weekly Lonapegsomatropin in Treatment\u2013Na\u00efve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"],"prefix":"10.1210","volume":"106","author":[{"given":"Paul S","family":"Thornton","sequence":"first","affiliation":[{"name":"Cook Children\u2019s Medical Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristides K","family":"Maniatis","sequence":"additional","affiliation":[{"name":"Rocky Mountain Pediatric Endocrinology, Centennial, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Aghajanova","sequence":"additional","affiliation":[{"name":"Yerevan State Medical University, Yerevan, Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chertok","sequence":"additional","affiliation":[{"name":"Voronezh State Medical University, Voronezh, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpis","family":"Vlachopapadopoulou","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital P.A. Kyriakou, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengning","family":"Lin","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Song","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Dam","family":"Christoffersen","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, A\/S, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke Miller","family":"Breinholt","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, A\/S, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"Republican Children\u2019s Clinical Hospital of the Ministry of Health of the Udmurt Republic, Izhevsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elene","family":"Giorgadze","sequence":"additional","affiliation":[{"name":"LTD National Institute of Endocrinology, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Korpal-Szczyrska","sequence":"additional","affiliation":[{"name":"Medical University of Gdansk, Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Hofman","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Karpf","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5289","authenticated-orcid":false,"given":"Aimee D","family":"Shu","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beckert","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, A\/S, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"2021120108543843100_CIT0001","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1874216501206010068","article-title":"The involvement of the GH\/IGF-I axis in cognitive functions of adult patients and healthy subjects","volume":"6","author":"Deijen","year":"2012","journal-title":"Open Endocrinol J"},{"issue":"1","key":"2021120108543843100_CIT0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/EJE-11-0558","article-title":"Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis","volume":"166","author":"Hazem","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2021120108543843100_CIT0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12020-014-0327-6","article-title":"GH and the cardiovascular system: an update on a topic at heart","volume":"48","author":"Isgaard","year":"2015","journal-title":"Endocrine."},{"issue":"2","key":"2021120108543843100_CIT0004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr Rev."},{"issue":"12","key":"2021120108543843100_CIT0005","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1210\/jcem.84.12.6189","article-title":"Four decades of growth hormone therapy for short children: what have we achieved?","volume":"84","author":"Guyda","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021120108543843100_CIT0006","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000350251","article-title":"Understanding the growth hormone therapy adherence paradigm: a systematic review","volume":"79","author":"Fisher","year":"2013","journal-title":"Horm Res Paediatr."},{"issue":"6","key":"2021120108543843100_CIT0007","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-16-0111","article-title":"Growth hormone research society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2021120108543843100_CIT0008","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2016-3776","article-title":"A randomized Phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021120108543843100_CIT0009","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1530\/EC-17-0203","article-title":"The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency","volume":"6","author":"Sprog\u00f8e","year":"2017","journal-title":"Endocr Connect."},{"issue":"3","key":"2021120108543843100_CIT0010","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/adc.51.3.170","article-title":"Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty","volume":"51","author":"Tanner","year":"1976","journal-title":"Arch Dis Child."},{"issue":"246","key":"2021120108543843100_CIT0011","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat 11"},{"issue":"4","key":"2021120108543843100_CIT0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/03014460050044874","article-title":"Galton\u2019s midparent height revisited","volume":"27","author":"Cole","year":"2000","journal-title":"Ann Hum Biol."},{"issue":"220","key":"2021120108543843100_CIT0013","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/adc.41.220.613","article-title":"Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II","volume":"41","author":"Tanner","year":"1966","journal-title":"Arch Dis Child."},{"issue":"219","key":"2021120108543843100_CIT0014","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/adc.41.219.454","article-title":"Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I","volume":"41","author":"Tanner","year":"1966","journal-title":"Arch Dis Child."},{"issue":"5","key":"2021120108543843100_CIT0015","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021120108543843100_CIT0016","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1210\/jc.2013-3060","article-title":"Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays","volume":"99","author":"Friedrich","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021120108543843100_CIT0017","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1210\/jcem.86.10.7932","article-title":"A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency","volume":"86","author":"Reiter","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021120108543843100_CIT0018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1530\/EJE-11-0536","article-title":"Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics","volume":"165","author":"de Schepper","year":"2011","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2021120108543843100_CIT0019","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-09-0422","article-title":"Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH","volume":"161","author":"Touraine","year":"2009","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2021120108543843100_CIT0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/jc.2013-2502","article-title":"24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency","volume":"99","author":"Khadilkar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2021120108543843100_CIT0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000351025","article-title":"Personalized approach to growth hormone treatment: clinical use of growth prediction models","volume":"79","author":"Wit","year":"2013","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"2021120108543843100_CIT0022","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000448553","article-title":"Validation of prediction models for near adult height in children with idiopathic growth hormone deficiency treated with growth hormone: a belgian registry study","volume":"86","author":"Straetemans","year":"2016","journal-title":"Horm Res Paediatr."},{"issue":"3","key":"2021120108543843100_CIT0023","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1210\/jc.2009-1471","article-title":"Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables","volume":"95","author":"Ranke","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021120108543843100_CIT0024","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial","volume":"105","author":"Savendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2021120108543843100_CIT0025","doi-asserted-by":"crossref","first-page":"OR10","DOI":"10.1210\/jendso\/bvaa046.1279","article-title":"OR10-06 somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric phase 3 clinical trial","volume":"4","author":"Deal","year":"2020","journal-title":"J Endocr Soc"},{"issue":"8","key":"2021120108543843100_CIT0026","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1210\/jc.2009-0638","article-title":"The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects","volume":"94","author":"Surya","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021120108543843100_CIT0027","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1210\/jcem-70-1-207","article-title":"Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites","volume":"70","author":"J\u00f8rgensen","year":"1990","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021120108543843100_CIT0028","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2265.1996.00814.x","article-title":"Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients","volume":"45","author":"Laursen","year":"1996","journal-title":"Clin Endocrinol."},{"issue":"1","key":"2021120108543843100_CIT0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ar.a.20272","article-title":"In vivo delivery of fluoresceinated dextrans to the murine growth plate: imaging of three vascular routes by multiphoton microscopy","volume":"288","author":"Farnum","year":"2006","journal-title":"Anat Rec A Discov Mol Cell Evol Biol."},{"issue":"3","key":"2021120108543843100_CIT0030","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1210\/jc.2004-0812","article-title":"Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence","volume":"90","author":"L\u00f6fqvist","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021120108543843100_CIT0031","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/cen.12464","article-title":"Is growth hormone treatment in children associated with weight gain?\u2013longitudinal analysis of KIGS data","volume":"81","author":"Reinehr","year":"2014","journal-title":"Clin Endocrinol."},{"key":"2021120108543843100_CIT0032","first-page":"41","article-title":"Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database","volume":"68","author":"Darendeliler","year":"2007","journal-title":"Horm Res."},{"issue":"2","key":"2021120108543843100_CIT0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00148581-200406020-00003","article-title":"Growth hormone treatment in children: review of safety and efficacy","volume":"6","author":"Harris","year":"2004","journal-title":"Paediatr Drugs."},{"issue":"4","key":"2021120108543843100_CIT0034","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/cen.13502","article-title":"Long-term safety of growth hormone-A combined registry analysis","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol."},{"key":"2021120108543843100_CIT0035","author":"Rau","year":"2010"},{"issue":"10","key":"2021120108543843100_CIT0036","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1210\/jcem.85.10.6881","article-title":"Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections","volume":"85","author":"Amato","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021120108543843100_CIT0037","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.clinthera.2015.05.505","article-title":"Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy","volume":"37","author":"Iglay","year":"2015","journal-title":"Clin Ther."},{"issue":"2","key":"2021120108543843100_CIT0038","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/14737167.7.2.187","article-title":"Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006)","volume":"7","author":"Shi","year":"2007","journal-title":"Expert Rev Pharmacoecon Outcomes Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab529\/39628994\/dgab529.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/11\/3184\/41378744\/dgab529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/11\/3184\/41378744\/dgab529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:45:16Z","timestamp":1638366316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/11\/3184\/6323258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,17]]},"published-print":{"date-parts":[[2021,10,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab529","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,7,17]]}}}